14 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jul 2028. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
12
Ending by 2030
Jul 2028
Next term end
2
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Nov 2032 · High confidence
Also notable
Ends Jul 2037 · High confidence
Dermal Delivery Compositions and Methods
US 9,364,487
Cited by 53 later US patents, top 10% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Transdermal Packaging Membranes
US 12,226,534
Granted 2025. Too new for citation comparison; protection runs to 2037.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 9, 2026The maintenance fee for Dermal Delivery Device (US 9,050,348) comes due Dec 9, 2026. Unpaid by Jun 9, 2027, it lapses early.
- 1 fee due May 24, 2027The maintenance fee for Contraceptive Transdermal Delivery of Hormones (US 9,192,614) comes due May 24, 2027. Unpaid by Nov 24, 2027, it lapses early.
- 3 fees due Jun 1, 2027
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Dermal Delivery Device with Reduced Loss of Its Volatile Components | 13 in force | to Nov 2032 |
| Transdermal Packaging Membranes | 1 in force | to Jul 2037 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,747,888 | Dermal Delivery Device with in Situ Seal In force · High confidence | In force | High confidence | |
| US 9,050,348 | Dermal Delivery Device In force · High confidence | In force | High confidence | |
| US 12,070,520 | Dermal Delivery Device In force · High confidence | In force | High confidence | |
| US 8,246,978 | Dermal Delivery Device with Reduced Loss of Its Volatile Components In force · High confidence | In force | High confidence | |
| US 9,775,817 | Transdermal Contraceptive Hormones Delivery In force · High confidence | In force | High confidence | |
| US 9,775,847 | Transdermal Contraceptive Hormones Delivery In force · High confidence | In force | High confidence | |
| US 9,775,848 | Transdermal Contraceptive Hormones Delivery In force · High confidence | In force | High confidence | |
| US 9,782,419 | Transdermal Contraceptive Hormones Delivery In force · High confidence | In force | High confidence | |
| US 9,192,614 | Contraceptive Transdermal Delivery of Hormones In force · High confidence | In force | High confidence | |
| US 9,198,876 | Contraceptive Transdermal Delivery of Hormones In force · High confidence | In force | High confidence |
Also on record, not counted in the 14: 5 patents ended · 4 applications pending · 23 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.